| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5753627 | CURIUM | Use of certain complexed somatostatin peptides for the invivo imaging of somatostatin receptor-positive tumors and metastasis |
May, 2015
(9 years ago) | |
| US5776894 | CURIUM | Chelated somatostatin peptides and complexes thereof, pharmaceutical compositions containing them and their use in treating tumors |
Jul, 2015
(8 years ago) | |
| US6123916 | CURIUM | Therapeutic use of somatostatin peptides |
Sep, 2017
(6 years ago) | |
Octreoscan is owned by Curium.
Octreoscan contains Indium In-111 Pentetreotide Kit.
Octreoscan has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Octreoscan are:
- US5753627
- US5776894
- US6123916
Octreoscan was authorised for market use on 02 June, 1994.
Octreoscan is available in injectable;injection dosage forms.
Octreoscan can be used as method for the detection of neuroendocrine tumors.
The generics of Octreoscan are possible to be released after 26 September, 2017.
Drugs and Companies using INDIUM IN-111 PENTETREOTIDE KIT ingredient
Market Authorisation Date: 02 June, 1994
Treatment: Method for the detection of neuroendocrine tumors
Dosage: INJECTABLE;INJECTION
More Information on Dosage
OCTREOSCAN family patents
